ABSI
AbsciDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
A successful licensing deal or a positive platform-driven discovery outcome re-rates Absci toward a mid-single-digit multiple as revenue visibility improves and dilution is minimized.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.0.
What can break
Failure to secure partners or the need for dilutive financing amid continued R&D expenses drives the share down materially; limited near-term revenue keeps downside elevated.
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.34 · Bull $4.21 · Bear $1.17
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $13.78
Why
Momentum99 · Δ7d +0.0
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 99.4 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.38B
Beta
2.13
Shares Out
169.4M
P/E (TTM) · Derived
-9.7
P/S (TTM)
199.78
P/FCF (TTM) · Derived
-12.00
Rev YoY
-81.8%
EPS YoY
-8.6%
Gross Margin
-520.8%
Op Margin
-4261.1%
Net Debt
-$138.99M
Current Ratio
6.59
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology